Final program - Societa' Italiana di Cancerologia

Pagina creata da Angelo Crippa
 
CONTINUA A LEGGERE
Final program - Societa' Italiana di Cancerologia
Final program
Final program - Societa' Italiana di Cancerologia
UNDER THE AUSPICE OF

della Fondazione per esteso

                                         SUPPORTED BY

                                                             FAMIGLIA DI
                                                             ELENA
                                                           CAPPANNINI

                              FONDAZIONE AIRC PER LA RICERCA SUL CANCRO
Final program - Societa' Italiana di Cancerologia
Comitati

SCIENTIFIC COORDINATOR
Nicola Normanno (National Cancer Institute “G. Pascale”, Naples)

LOCAL SCIENTIFIC AND ORGANIZING COMMITTEE
Gerardo Botti (National Cancer Institute “G. Pascale”, Naples)
Lucia Altucci (University of Campania “Luigi Vanvitelli”, Naples)
Roberto Bianco (University “Federico II”, Naples)
Alfredo Budillon (National Cancer Institute “G. Pascale”, Naples)
Luigi Buonaguro (National Cancer Institute “G. Pascale”, Naples)
Fortunato Ciardiello (University of Campania “Luigi Vanvitelli”, Naples)
Vittorio Colantuoni (University of Sannio, Benevento)
Daniela Corda (Institute of Protein Biochemistry - National Research Council (CNR), Naples)
Rosamarina Melillo (University “Federico II”, Naples)
Francesco Perrone (National Cancer Institute “G. Pascale”, Naples)
Stefania Scala (National Cancer Institute “G. Pascale”, Naples)

SIC SCIENTIFIC BOARD
President
Gabriella Sozzi (IRCCS National Cancer Institute, Milan, Italy)

President Elect
Nicola Normanno (National Cancer Institute “G. Pascale”, Naples, Italy)

Board
Paola Chiarugi (University of Florence, Italy)
Amedeo Columbano (University of Cagliari, Italy)
Rita Falcioni (Regina Elena National Cancer Institute, Rome, Italy)
Davide Melisi (University of Verona, Italy)
Katia Scotlandi (IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy)
Elda Tagliabue (IRCCS National Cancer Institute, Milan, Italy)
Giulia Taraboletti (“Mario Negri” Institute for Pharmacological Research, Bergamo, Italy)

Members under 35
Antonino Bruno (MultiMedica, Milan)
Marco Macagno (University of Turin)

Past President
Silvia Giordano (University of Turin)                                                         SIC Secretariat
                                                                                              Società Italiana di Cancerologia
                                                                                              Via G. Venezian, 1 - 20133 Milano MI
                                                                                              E-mail: sic@istitutotumori.mi.it
                                                                                              www.cancerologia.it

                                                                                              Organizing Secretariat

                                                                                              Via Sassonia, 30 - 47922 Rimini RN
                                                                                              E-mail: sic2019@adriacongrex.it
                                                                                              www.adriacongrex.it

                                                                    1
Faculty

Lucia Altucci               Campania University “Luigi Vanvitelli”, Naples, Italy
Guillem Argilés             Vall d’Hebrón University Hospital, Barcelona, Spain
Ludovic Barault             Candiolo Cancer Institute, FPO-IRCCS, Candiolo TO, Italy
Fabrizio Bianchi            IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo FG, Italy
Roberto Bianco              University “Federico II”, Naples, Italy
Antonino Bruno              Multimedica, Milan, Italy
Alfredo Budillon            National Cancer Institute “G. Pascale”, Naples, Italy
Federico Caligaris Cappio   President Associazione Italiana per la Ricerca sul Cancro, Milan, Italy
Michele Ceccarelli          Sannio University, Benevento, Italy
Paola Chiarugi              University of Florence, Italy
Vittorio Colantuoni         University of Sannio, Benevento, Italy
Amedeo Columbano            University of Cagliari, Italy
Daniela Corda               Institute of Protein Biochemistry - National Research Council (CNR), Naples, Italy
Elisabetta Dejana           University of Milan IFOM, Milan, Italy
Federica Di Nicolantonio    University of Turin, Italy
Riccardo Dolcetti           The University of Queensland Diamantina Institute, Brisbane, Australia
Manel Esteller              Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain
Rita Falcioni               Regina Elena National Cancer Institute, Rome, Italy
Christian Frezza            University of Cambridge, United Kingdom
Silvia Giordano             University of Turin, Italy
Elena Jachetti              IRCCS National Cancer Institute, Milan, Italy
Marco Macagno               University of Turin, Italy
Sara Mainardi               The Netherlands Cancer Institute, Amsterdam, The Netherlands
Ilaria Malanchi             The Francis Crick Institute, London, UK
Erika Martinelli            Campania University “Luigi Vanvitelli”, Naples, Italy
Rosamarina Melillo          University “Federico II”, Naples, Italy
Davide Melisi               University of Verona, Italy
Saverio Minucci             University of Milan, Italy
Clara Montagut              MIM Hospital del Mar Medical Research Institute, Barcelona, Spain
Nicola Normanno             National Cancer Institute “G. Pascale”, Naples, Italy
Gabriele Picco              Wellcome Sanger Institute Hinxton, Cambridge, United Kingdom
Maria Rescigno              Humanitas University, Milan, Italy
Antoni Ribas                University of California, Los Angeles, USA
Licia Rivoltini             IRCCS National Cancer Institute, Milan, Italy
Stefania Scala              National Cancer Institute “G. Pascale”, Naples, Italy
Katia Scotlandi             IRCCS Orthopaedic Rizzoli Institute, Bologna, Italy
Gabriella Sozzi             IRCCS National Cancer Institute, Milan, Italy
Elda Tagliabue              IRCCS National Cancer Institute, Milan, Italy
Giulia Taraboletti          “Mario Negri” Institute for Pharmacological Research, Bergamo, Italy
Jean Claude Zenklusen       National Cancer Institute, Bethesda, USA

                                                             2
Program at a Glance
    Wednesday, 6               Thursday, 7 November 2019                    Friday, 8 November 2019
   November 2019
   Plenary Room           Plenary Room         Partenope Room         Plenary Room         Partenope Room
                                                                         Lecture
                                                                        8.30-8.50

                       Epigenetics and non                           Immunotherapy:
                        coding RNAs: from                          from the rationale to
                         basic science to                           clinic applications
                       clinical applications                            08.50-10.00
                            08.30-10.00

                           Coffee Break
                           10.00-10.15                                 Coffee Break
                                                                       10.00-10.30
                           SIC meets
                         Pharma Industry
                           10.15-12.00
                                                                   Poster discussion 2A Poster discussion 2B
                                                                       10.30-12.00          10.30-12.00
    Registration
       12.00
                       Poster discussion 1A Poster discussion 1B
                           12.00-13.30          12.00-13.30
                                                                     Poster viewing
  Opening Address                                                     with authors
    13.00 - 14.00                                                   (Mirabilis Room)
                              Lunch                                   12.00-13.00
                           13.30 - 14.30

  Opening Lecture         Poster viewing                                  Lunch
    14.00 -15.00           with authors                                13.00 - 14.00
                         (Mirabilis Room)
    Coffee Break           14.30-15.30
    15.00 - 15.30                                                  Tumor progression,
                                                                    microenvironment
                       Tumor cell metabolism                         and metastases
                           15.30-17.00                                 14.00-15.30
 Precision medicine:
  biomarkers driven
      oncology             Coffee Break
     15.30 -17.00          17.00-17.15                               Closing Lecture
                                                                      15.30 - 16.15

                         SIC/ESMO/EACR -
  Award Ceremony        Young investigators                         Award Ceremony
    17.00 -17.30            17.15 - 18.30                             16.15 - 16.45

   Mechanisms of          “Giorgio Prodi”
 resistance to anti-          Lecture
   cancer therapy
    17.30 -19.00           18.30 - 19.15

                       SIC General Assembly
                            19.15 - 19.45
  Congress Event

                       Get together cocktail

                                                    3
Wednesday, November 6th

12.00             Registration

13.00 - 14.00     Opening Address

14.00-15.00       Opening Lecture                                                                                          Plenary Room
                  The Cancer Genome Atlas and beyond: Taking genomics to the clinic
                  Jean Claude Zenklusen, Bethesda (USA)

15.00-15.30       Coffee break

15.30-17.00       Precision medicine: biomarkers driven oncology                                                           Plenary Room
                  Chairs: Rita Falcioni, Rome (Italy) - Elda Tagliabue, Milan (Italy)

                  Large scale systems biology and bioinformatics in cancer genomics
                  Michele Ceccarelli, Benevento (Italy)

              R1 An integrated multi-omic approach for prognostically relevant subtypes classification of ovarian cancer
                 patients
                 D. Mezzanzanica (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy),
                 S. Pignata, D. Califano, S. Canevari, S. Losito, G. Baldassarre, F. Perrone, M. Bagnoli, L. De Cecco

                  Potential Clinical Utility of analysing circulating tumor DNA for CRC
                  Clara Montagut, Barcelona (Spain)

              N1 Pharmacological inhibition of the ALK/MET axis elicits therapeutic potential in consensus molecular
                 subtype 1 colon cancer patients
                 M. Mazzeschi (University of Bologna, Italy), M. Sgarzi, A. Romanzi, V. Gelfo, M. Cardi, S. Santi, M. Fiorentino,
                 A. Ardizzoni, B. Gyorffy, Y. Yarden, G. D’ Uva, M. Lauriola

17.00-17.30       Award Ceremony                                                                                           Plenary Room
                  “Elena Cappannini” award for the best 2018 publication
                  “Pezcoller Foudation-SIC - Patrizia Coser” Fellowship 2020-2021

17.30-19.00       Mechanisms of resistance to anti-cancer therapy                                                          Plenary Room
                  Chairs: Silvia Giordano, Turin (Italy) - Davide Melisi, Verona (Italy)

                  Prioritisation of cancer therapeutic targets using CRISPR (Clustered Regularly Interspaced Short Palindromic
                  Repeats)-Cas9 screens
                  Gabriele Picco, Cambridge (UK)

           I1     PAK1 as a novel mediator of resistance to endocrine therapy and CDK4/6 inhibitors in ER+/PAK1 amplified
                  breast cancer
                  S. Belli (University of Naples “Federico II”, Naples, Italy) C. Di Mauro, D. Esposito, A. Pesapane, F. Napolitano,
                  A. Santaniello, P. De Placido, P. Cascetta, A. Carratù, E. Mozzillo, R. Marciano, A. Servetto, R. Bianco, L. Formisano

                  The RAS paradigm revisited: implications for targeted therapy resistance and the identification of
                  effective drug combinations for RAS mutant tumors
                  Sara Mainardi, Amsterdam (NL)

           H2 Combined treatment with parp and CHK1 inhibitors: a new strategy for the treatment of the MYCN-
              amplified neuroblastoma
              S. Di Giulio (University of Rome “La Sapienza”, Rome, Italy, M. Petroni, V. Colicchia, F. Pedretti, F. Pastorino, F. Fabretti,
              V. Nicolis Di Robilant, R. Cepollaro, F. Belardinilli, G. Scafetta, G. Peruzzi, V. Ramponi, P. Infante, M. Moretti, A. Coppa,
              A. Bartolazzi, M. Ponzoni, G. Giannini

                                                                    4
Thursday, November 7th

8.30-10.00        Epigenetics and non coding RNAs (RiboNucleic Acid):
                  from basic science to clinical applications                                                              Plenary Room
                  Chairs: Katia Scotlandi, Bologna (Italy) - Gabriella Sozzi, Milan (Italy)

                  Epigenome deregulation in cancer: drug discovery approaches for prevention and treatment
                  Lucia Altucci, Naples (Italy)

             H1 MiR-302b-mediated BRCAness improves sensitivity to PARP inhibitors in BRCA-1 not-mutated TNBC
                A. Cataldo (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)
                I. Plantamura, S. Romero-Cordoba, G. Cosentino, M.V. Iorio

                  Cancer Epigenetics: From Knowledge to Applications
                  Manel Esteller, Barcelona (Spain)

             F1   MiR-214 in tumor-stroma cell interactions
                  F. Orso, F. Virga, D. Dettori, M. Paradzik, D. Baruffaldi, A. Massa, M. Van Wynendaele, E. Bolli, F. Cavallo, M. Forni,
                  L. Salmena, M. Mazzone, P.P. Pandolfi, D. Taverna (University of Torino and MBC, Turin, Italy)

10.00-10.15       Coffee break

10.15-12.00       SIC meets Pharma Industry                                               Not accredited CME Session Plenary Room

                  The Future of Precision Medicine: a Roche perspective
                  Roberto Scalamogna, Monza (Italy)

                  From myeloid cell differentiation marker to therapeutic target in acute myeloid leukemia: the long journey
                  of CD157  
                  Enza Ferrero, Turin (Italy) - Yuliya Yakymiv, Turin (Italy)

                  TruSight Oncology 500, a comprehensive assay for genomic profiling and beyond
                  Gina De Bonis, Milan (Italy)

                  AstraZeneca Oncology Commitment to Lung Cancer
                  Giovanni Melillo, Milan (Italy)

                                                                     5
Thursday, November 7th

12.00-13.30    Poster Discussion 1A
               PRECISION MEDICINE                                                                                         Plenary Room
               Chairs: Federica Di Nicolantonio, Turin (Italy) - Erika Martinelli, Naples (Italy)

          A4 Development and exploitation of a mouse model of intrahepatic cholangiocarcinoma driven by oncogenic
             FGFR2 fusions
             G. Cristinziano (IRCCS Regina Elena National Cancer Institute, Rome, Italy), M. Porru, D. Lamberti, C.A. Amoreo, S.
             Buglioni, M.G. Diodoro, M.J. Borad, C. Leonetti, S. Anastasi, O. Segatto

          E7   Fatty acid uptake as novel actionable target of HER2-positive breast cancer stem cells resistant to targeted
               therapy
               L. Castagnoli, C. Vernieri, E. Fasano, A. Belfiore, S. Faraci, P. Corsetto, A. Rizzo, A. Vingiani, M. Di Nicola, M. Dugo, G.
               Pruneri, E. Tagliabue, S. Pupa (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

          I5   Tumor-stroma interactions mediated by Semaphorin 6A as a determinant of drug resistance in BRAF-Mut
               melanoma
               R. Loria (IRCCS Regina Elena National Cancer Institute, Rome, Italy), I. Falcone, M. Di Martile, V. Caprara, R. Fraioli, V.
               Laquintana, L. Rosanò, D. Del Bufalo, L. Ciuffreda, M. Milella, R. Falcioni

          K36 A novel mechanism of induction of anticancer adaptive immunity elicited by BoxA, a fragment of HMGB1
              G. D’Agostino (Universita’ degli studi del Sannio, Benevento, Italy)

          L3   p27kip1 regulates haematopoiesis by inducing notch signaling pathway
               I. Segatto, G.L. Rampioni Vinciguerra, F. Citron, D. Viotto, A. Vecchione, B. Belletti,
               G. Baldassarre (Centro di Riferimento Oncologico di Aviano (CRO), Aviano, Italy)

          N4 Dynamics of RAS/BRAF mutations in cfDNA from metastatic colorectal carcinoma patients enrolled in the
             ermes clinical trial
             A.M. Rachiglio (Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS Naples, Italy), L. Forgione, R. Pasquale, C.
             Roma, E. Maiello, F. Di Costanzo, A. Cassata, E. Tamburini, G. Tonini, R. Bordonaro, G. Rosati, A. Zaniboni, S. Lonardi,
             D. Ferrari, G.L. Frassineti, S. Tamberi, S. Pisconti, F. Di Fabio, C. Pinto, N. Normanno

          O4 Circulating tumor DNA as a follow-up monitoring tool in triple negative breast cancer patients
             Ortolan E. (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), V. Appierto, S. Di Cosimo, S. Veneroni, C. De
             Marco, E. Cavadini, G. Pruneri, G. Bianchi, M.G. Daidone

          P8   Plasmatic CXCL8 is a marker for TGFß-activated kinase 1 (TAK1) activation which may predict resistance
               to nanoliposomal irinotecan (nal-IRI) in gemcitabine-refractory pancreatic cancer (PC) patients
               R. Santoro (University of Verona, Italy), V. Merz, C. Zecchetto, F. Simionato, G. Piro, F. Sabbadini, A. Cavaliere, S.
               Casalino, A. Auriemma, D. Melisi

                                                                  6
Thursday, November 7th

12.00-13.30    Poster Discussion 1B
               TUMOR IMMUNOLOGY AND MICROENVIRONMENT                                                                   Partenope Room
               Chairs: Daniela Corda, Naples (Italy) - Rosa Marina Melillo, Naples (Italy)

          C1   High somatic mutation and neoantigen burden do not correlate with decreased progression-free survival in
               HCC patients not undergoing immunotherapy
               A. Mauriello, R. Zeuli, B. Cavalluzzo, A.C. Petrizzo, M.L. Tornesello, F.M. Buonaguro, M. Ceccarelli, M. Tagliamonte
               (Istituto Nazionale Tumori “Pascale”, Naples, Italy), L. Buonaguro

          O1 Multiparametric immune profiling to predict the risk of cancer development in solid organ transplant
             patients
             M. Cangemi (Centro di Riferimento Oncologico di Aviano, Italy), E. Rampazzo, S. Zanussi, D. Martorelli, R.M. Tedeschi,
             A. De Rossi, A. Steffan, R. Dolcetti, E. Vaccher E.

          T2   Modulation of the pulmonary microbiota as a new approach to treat and prevent cancer and metastasis of
               various histotypes in the lung
               V.M. Le Noci (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), S. Guglielmetti, S. Arioli, M. Sommariva, F.
               Bianchi, T. Triulzi, A. Balsari, E. Tagliabue, L. Sfondrini

          T4   Secretion of the pro-inflammatory cytokine IFNg produced by activated NK and GD2 redirected CAR-T
               cells overcomes MycN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape
               M. Caforio (Bambino Gesù Children’s Hospital, Rome, Italy), C. Sorino, I. Caruana, G. Weber, A. Camera, L. Cifaldi, B.
               De Angelis, A. Vitale, B.M. Goffredo, M. Compagnone, D. Fruci, C. Quintarelli, M. Fanciulli, F. Locatelli, V. Folgiero

          T6   An intrinsic PD-1 circuit sustains proliferation and motility of thyroid cancer cells through a SHP2/Ras/Raf/
               Erk signaling cascade
               F. Liotti (University of Naples “Federico II”, Naples, Italy), N. Kumar, N. Prevete, M. Marotta, S. Moretti, S. Paladino, C.
               Ierano, P. Rea, R. Franco, S. Scala , E. Puxeddu, R. M. Melillo

          T16 Preclinical validation of mesothelin as a new immunotherapeutic target for aggressive colorectal cancer
              E. Torchiaro (Candiolo Cancer Institute, Candiolo, Italy), M. Cortese, C. Petti, V. Leuci, R. Rotolo, D. Sangiolo, E. Medico

          T21 Immunogenic tumor cell lysates modulate coding and non-coding RNA profiles of dendritic cell vaccine
              based on immunogenic cell death
              J. Dal Col (Univerity of the study of Salerno, Italy), M. Ravo, B. Montico, G. Giurato, D. Memoli, R. Tarallo, A. Nigro, L.
              Ricciardi, A. Weisz, A. Steffan, R. Dolcetti, C. Stellato, D.A. Faè, V. Casolaro

          U4 Tumor Associated Macrophages: Toward A Better Understanding Of Their Cancer Driver Capability In
             Malignant Pleural Mesothelioma
             E. Digifico (Humanitas University Pieve Emanuele, Italy), M. Erreni, G.L. Ceresoli, M. Roncalli, R. Frapolli, M. D’ Incalci,
             C. Belgiovine, P. Allavena

13.30-14.30    Lunch

14.30-15.30    Poster viewing with authors                                                                               Mirabilis Room

                                                                  7
Thursday, November 7th

15.30-17.00    Tumor cell metabolism                                                                                  Plenary Room
               Chairs: Paola Chiarugi, Florence (Italy) - Amedeo Columbano, Cagliari (Italy)

               The role of mitochondria in cancer
               Christian Frezza, Cambridge (UK)

          G2 Targeting of glutamine synthetase skews macrophages towards a M1-like phenotype and inhibits tumor
             metastasis
             A. Castegna (University of Bari, Italy), A. Menga, M. Mazzone

               Tackling metabolic plasticity of tumor cells
               Saverio Minucci, Milan (Italy)

          G1 Reprogramming of amino acid transporters induces aspartate and glutamate dependency and drives
             endocrine resistance in breast cancer
             M. Bacci, N. Lorito, L. Ippolito, M. Ramazzotti, S. Luti, S. Romagnoli, M. Parri, F. Bianchini, F. Cappellesso, F. Virga,
             Q. Gao, B.M. Simões, E. Marangoni, L.A. Martin, G. Comito, M. Ferracin, E. Giannoni, M. Mazzone, P. Chiarugi,
             A. Morandi (University of Florence, Italy)

17.00-17.15    Coffee break

17.15-18.30    SIC (Società Italiana Cancerologia)                                                                    Plenary Room
               ESMO (European Society for Medical Oncology)
               EACR (European Association for Cancer Research)
               Young investigators
               Chairs: Antonino Bruno, Milan (Italy) - Marco Macagno, Turin (Italy)

               Stromal accomplices drive neuroendocrine features and immune escape in prostate cancer
               Elena Jachetti, Milan (Italy)

               Finding a career path for a medical oncologist in current European panorama
               Guillem Argilés, Barcelona (Spain)

               From convincing yourself to convincing others
               Ludovic Barault, Candiolo Turin (Italy)

18.30-19.15    “Giorgio Prodi” Lecture                                                                                Plenary Room
               Infection-driven tumors: a career lesson for cancer immunotherapy
               Riccardo Dolcetti, Brisbane (Australia)

19.15-19.45    SIC General Assembly

                                                                 8
Friday, November 8th

                                                                                                                                                          Plenary Room

8.30-8.50         The HEPAMUT project:
                  a road to personalized therapeutic cancer vaccine for liver cancer                                         *Not accredited CME Lecture
                  Luigi Buonaguro, Naples, Italy

8.50-10.00        Immunotherapy: from the rationale to clinic applications                                                                                Plenary Room
                  Chairs: Federico Caligaris Cappio, Milan (Italy) - Nicola Normanno, Naples (Italy)

                  Myeloid cells as biomarker and immunomodulating target in cancer
                  Licia Rivoltini (Milan, Italy)
                                                                                                    A - Marchio con nome della Fondazione per esteso

             T1   NK cells specifically TCR-dressed to kill cancer cells                            Versione su una riga

                  N. Mensali (Oslo University Hospital, Norway) P. Dillard, M. Hebeisen, S. Lorenz, T. Theodossiou, M. Myhre, A. Fåne,
                  G. Gaudernack, G. Kvalheim, J. Myklebust, E. Inderberg, S. Wälchli

                  Response and resistance to PD-1 blockade therapy                                                                    supported by
                  Antoni Ribas, Los Angeles (USA)

10.00-10.30       Coffee break

10.30-13.00       Poster Discussion 2A
                  CANCER GENETICS, EPIGENETICS AND TUMOR PROGRESSION                                           Plenary Room
                  Chairs: Fabrizio Bianchi, San Giovanni Rotondo (Italy) - Vittorio Colantuoni, Benevento (Italy)                                      FONDAZIONE AIRC PER LA RICERCA SUL CANCRO

             B2   Exploring the transcriptional landscape of MBCs characterized for germline mutations in homologous
                  recombination genes by RNA-sequencing
                  V. Zelli (Sapienza University of Rome, Italy), V. Silvestri, V. Valentini, A. Bucalo, P. Rizzolo, I. Zanna, L. Cortesi, D. Calistri,
                  M.G. Tibiletti, G. Giannini, S.B. Fox, D. Palli, L. Ottini

             C4   The transcriptional landscape of an aggressive lung adenocarcinoma molecular subtype
                  V. Melocchi (Fondazione IRCCS - Casa Sollievo della Sofferenza, Unit of Oncology Biomarkers, San Giovanni Rotondo -
                  FG, Italy), F. Mazzarelli, E. Dama, T. Colangelo, R. Cuttano, F. Bianchi

             C11 Molecular olecular characterization of estrogen recptor β actions in triple negative breast cancer
                 G. Pecoraro (University of Salerno, Italy), E. Alexandrova, P. Saggese, J. Lamberti, G. Giurato, M. Ravo, F. Collina,
                 M. Cantile, G. Botti, R. Tarallo, F. Rizzo, G. Nassa, A. Weisz

             C17 BCL6 regulates triple-negative breast cancer stem cells by suppressing the Notch pathway repressor NUMB
                 F. De Santis (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), T. Volpari S.L. Romero-Cordoba, S. Faraci,
                 O. Rondinone, F. Farris, L. Castagnoli, C. Puricelli, A. Koshorke, G. Fucà, R. Marullo, C. Tripodo, E. Tagliabue, L.
                 Cerchietti, F. De Braud, S.M. Pupa, M. Di Nicola

             C19 HMGA1 pseudogenes as oncogenic competitive endogenous RNAs
                 M. De Martino (Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, Naples Italy), A. Fusco, F. Esposito

             C29 Defination of a genetic signature to predict platinum resistance in ovarian cancer
                 C. De Marco (Università “Magna Graecia”, Catanzaro Italy), A. Di Cello, S. Migliozzi, C. Mignogna, D. Malanga, F. Zullo,
                 G. Viglietto

             F14 Lung cancer cells with hybrid phenotype possess the highest ability to initiate metastasis and negatively
                 modulate NK cells recruitment to metastatic site
                 F. Giovinazzo, C. Gardelli, G. Pollaci, P. Orecchia, M. Parodi, G. Centonze, L. Roz, M. Vitale, G. Sozzi, G. Bertolini
                 (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy)

             N12 Liquid biopsy as tool to monitor advanced non-small cell lung cancer (NSCLC) during systemic treatment
                 E. Zulato, L. Bonanno, I. Attili, A. Pavan, G. Nardo, P. Del Bianco, A. Boscolo Bragadin, M. Verza, L. Pasqualini,
                 G. Pasello, M. Fassan, M. Rugge, G.L. De Salvo, F. Calabrese, V. Guarneri, A. Amadori, P.F. Conte, S. Indraccolo (Istituto
                 Oncologico Veneto, IOV-IRCCS, Padova, Italy)

                                                                         9
Friday, November 8th

10.30-13.00    Poster Discussion 2B
               NOVEL THERAPUTIC APPROACHES AND DRUG RESISTANCE                                                      Partenope Room
               Chairs: Roberto Bianco, Naples (Italy) - Alfredo Budillon, Naples (Italy)

          E5   MYC modulates breast cancer stem cell response to PARP inhibitors via SAM68 and RAD51
               A. Turdo (University of Palemo, Italy), M. Gaggianesi, A. Chinnici, V. Veschi, D.S. Sardina, G. Ganduscio, F. Verona,
               M. Buffa, S. Ficarella, N. Faldetta, G. Stassi, M. Todaro

          E10 An in vitro preclinical approach to test drugs targeting chronic myeloid leukemia progenitor/stem cells
              I. Tusa (Department of Experimental and Clinical Biomedical Sciences, University of Florence, Italy), G. Cheloni,
              M. Poteti, A. Silvano, A. Tubita, A. Gozzini, P. Dello Sbarba, E. Rovida

          E12 Acute myeloid leukemia cells dysregulate normal hematopoiesis by releasing extracellular vesicles
              S. Trino (IRCCS Centro di Riferimento Oncologico della Basilicata (CROB), Rionero in Vulture, PZ, Italy), I. Laurenzana,
              D. Lamorte, M. Santodirocco, L. Di Mauro, P. Musto, L. De Luca, A. Caivano

          I21 A defective transcription coupled-nucleotide excision repair (TC-NER) as a possible cause of acquired
              resistance to trabectedin in myxoid liposarcoma patient derived xenograft (PDX) models
              I. Craparotta (Istituto di Ricerche Farmacologiche Mario Negri, Milan Italy), M. Mannarino, B.Ballabio, F. Frapolli,
              B. Bello, P. Ponzo, M. Marchini M., M. D’ Incalci

          L8   P21-activated kinases involvement in EGFR inhibitor resistant colorectal cancer
               D. Esposito, A. Pesapane (University of Naples “Federico II”, Naples Italy), C. Di Mauro, S. Belli, F. Napolitano,
               A. Santaniello, P. De Placido, P. Cascetta, A. Carratù E. Mozzillo, R. Marciano, A. Servetto, L. Formisano, R. Bianco

          N8 Oncogenic role of the aminopeptidase ERAP1 in Hedgehog-dependent cancer
             F. Bufalieri (University La Sapienza, Rome Italy), P. Infante, F. Bernardi, M. Caimano, M. Moretti, L. Lospinoso Severini,
             A. Peschiaroli, S. Pazzaglia, G. Melino, F. Locatelli, O. Ayrault, D. Fruci, L. Di Marcotullio

          P5   Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostgic factors for therapy
               response and survival in high grade serous ovarian cancer
               G. Benvenuto (University of Padova, Italy), P. Todeschini, L. Paracchini, E. Calura, R. Fruscio, C. Romani, L. Beltrame,
               P. Martini, A. Ravaggi, L. Ceppi, G. Sales, F. Donati, P. Perego, L. Zanotti, S. Ballabio, T. Grassi, M. Delle Marchette,
               G. Tognon, E. Sartori, M. Adorni, F. Odicino, M. D’Incalci, E. Bignotti, C. Romualdi, S. Marchini

          U5 Inducing cancer indolence by targeting mitochondrial Complex I is potentiated by blocking macrophage-
             mediated adaptive responses
             I. Kurelac (University of Bologna, Italy), L. Iommarini, R. Vatrinet, L.B. Amato, B. Kofler, I. Malanchi, A.M. Porcelli,
             G. Gasparre

12.00-13.00    Poster viewing with authors                                                                            Mirabilis Room

13.00-14.00    Lunch

                                                                 10
Friday, November 8th

14.00-15.30    Tumor progression, microenvironment and metastases                                                      Plenary Room
               Chairs: Stefania Scala, Naples (Italy) - Giulia Taraboletti, Bergamo (Italy)

               Deconstructing the metastatic microenvironment
               Ilaria Malanchi, London (UK)

          U2 NASH-related experimental liver carcinogenesis is critically affected by Hypoxia-inducible factor 2
             B. Foglia (University of Turin, Italy), S. Sutti, E. Morello, S. Cannito, C. Rosso, E. Novo, C. Bocca, M. Maggiora, V.
             Foscaldi, G.M. Villano, S. Bruzzì, N.N. Ramavath, R. Younes, P. Pontisso, E. Bugianesi, E. Albano, M. Parola

               Vascular malformations in cancer and other pathologies
               Elisabetta Dejana, Milan (Italy)

          U1 Multimerin-2 maintains vascular stability and permeability to control cancer cells dissemination
             E. Poletto (National Cancer Institute Aviano (CRO), IRCCS, Aviano, Italy) R. Pellicani E. Andreuzzi, A. Fejza, A. Paulitti,
             R. Colladel, G. Tarticchio, R. Doliana, P. Sabatelli, A. Colombatti, P. Bonaldo, M. Mongiat

15.30-16.15    Closing Lecture                                                                                         Plenary Room
               The microbiota in cancer progression
               Maria Rescigno, Milan (Italy)

16.15-16.45    Award Ceremony                                                                                          Plenary Room
               “Piero Trivella” Awards for the best posters
               “Guido Berlucchi Foundation” Awards for the best posters
               “Guido Berlucchi Foundation” Award for the best oral presentation

16.45          Closing remarks

                                                                 11
Scientific Information

CME CREDITS
No. 5,1 Italian Ministry of Health for the following Professions and Disciplines: Medical Surgeon (Disciplines: Haematology, General (Fa-
mily Doctors) Medicine, Medical Genetics, Oncology, Pathological Anatomy, Pharmacology and Clinical Toxicology, Clinical Pathology,
Internal Medicine); Biologist, Pharmacist, Chemist (Discipline: Analytical Chemistry); Physicist (Discipline: Health Physics); Veterinary
Surgeon.

SLIDES
Slides must be in English. Computer videoprojection will be available in Power Point. Please communicate to the Organizing Secretariat
your different requirements as soon as possible. Slides have to be handed to the slide centre one hour before the session beginning.

PRIZES
Wednesday, November 6th
• “Elena Cappannini” award for the best 2018 publication
• “Pezcoller Foudation-SIC - Patrizia Coser” Fellowship 2020-2021
Friday, November 8th
• “Piero Trivella” Awards for the best posters
• “Guido Berlucchi Foundation” Awards for the best posters
• “Guido Berlucchi Foundation” Award for the best oral presentation

General Information

Dates: November 6th-8th, 2019

Congress Venue: Hotel Royal Continental - Via Partenope 38/44 - Naples

How to reach the Congress Venue
By plane: From Napoli Capodichino airport take the Alibus busline and get off at Piazza Municipio. Continue on foot to via Acton and
take bus 154; get off at the stop for Saint Lucia, and the hotel is just a few steps away.
By train: From Napoli Centrale railway station, take Metro Line 1 (Garibaldi, just outside the station), going towards Dante, and get off
at Toledo. From there, you can take a taxi or enjoy a pleasant walk along Via Toledo and through Piazza del Plebiscito.
By car: From the motorway, drive towards Piazza Municipio/Porto, continue on Via Acton, cross the Tunnel della Vittoria and follow Via
Morelli. After 100m turn left into Piazza Vittoria.
Turn left to stay in the square and then turn left into via Arcoleo. Just before the entrance to the Tunnel della Vittoria, turn right into via
Chiatamone. At number 54, turn right into via Dumas and at the end of the road turn left into the garage of the hotel.

SIC Secretariat
Società Italiana di Cancerologia
Via Giacomo Venezian, 1 - 20133 Milano MI
E-mail: sic@istitutotumori.mi.it - www.cancerologia.it

Organizing Secretariat
Adria Congrex s.r.l.
Via Sassonia, 30 - 47922 Rimini RN
E-mail: sic2019@adriacongrex.it - www.adriacongrex.it

OFFICIAL LANGUAGE
English. Simultaneous translation will not be provided.

                                                                      12
General Information

BADGE
Participants and exhibitors are kindly requested to wear their badge during the congress.

CERTIFICATE OF ATTENDANCE
Certificate of attendance is given to all registered participants at the end of the congress.

EXHIBITION AND SPONSORSHIP
A technical, pharmaceutical and publication exhibition will be held in the Congress Venue. For any information please contact the
Organizing Secretariat.

REGISTRATION FEES
Registration Fees                                                                               On site Registration

SIC MEMBER (*)                                                                                       € 430,00

NON SIC MEMBER (**)                                                                                  € 530,00

SIC MEMBER UNDER 35 (*)                                                                              € 280,00

NON SIC MEMBER UNDER 35 (**)                                                                         € 350,00

(*)VAT non applicable as for law ex Art.4 DPR 633/72; (**) VAT included
The VAT rate will be applied depending on the Italian fiscal law at the time of payment.
Registration fees include:
• admission to the scientific sessions
• admission to the exhibition area
• name badge and congress kit
• welcome cocktail
• coffee breaks and light lunches
• abstracts book
• attendance certificate
• CME certificate
• social dinner

Payment Methods and Details
Payment on site: by cash or credit card (accepted VISA and MASTERCARD)
Cancellation
In case of cancellation no reimbursement is foreseen.

                                                                      13
Thanks to

   14
105
SIC Secretariat
Società Italiana di Cancerologia
      Via G. Venezian, 1
       20133 Milano MI
E-mail: sic@istitutotumori.mi.it
     www.cancerologia.it

   Organizing Secretariat

        Via Sassonia, 30
        47922 Rimini RN
E-mail: sic2019@adriacongrex.it
     www.adriacongrex.it
Puoi anche leggere